Transgene Secures Two Year Runway As Oncolytic Vaccine Enters Phase III
This article was originally published in Scrip
Transgene SA's share price has received a welcome boost this week on two separate pieces of news. Transgene's development partner SillaJen Inc. has begun the first Phase III trial of the oncolytic immunotherapy Pexa-Vec in patients with advanced liver cancer. Also, the company unveiled a new strategic development plan as well as the securing of €30m new financing.
Register for our free email digests: